Catalyst Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CATALYST PHARMS, and when can generic versions of CATALYST PHARMS drugs launch?
CATALYST PHARMS has four approved drugs.
There are fourteen US patents protecting CATALYST PHARMS drugs.
There are one hundred and thirty-three patent family members on CATALYST PHARMS drugs in thirty-four countries and nineteen supplementary protection certificates in fifteen countries.
Summary for Catalyst Pharms
| International Patents: | 133 |
| US Patents: | 14 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 4 |
Drugs and US Patents for Catalyst Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-004 | Oct 22, 2012 | RX | Yes | No | 6,949,571 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-005 | Oct 22, 2012 | RX | Yes | No | 6,949,571 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-002 | Oct 22, 2012 | RX | Yes | No | 8,772,497 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-006 | Oct 22, 2012 | RX | Yes | Yes | 8,772,497 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | 11,690,853 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CATALYST PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg | ➤ Subscribe | 2016-10-24 |
International Patents for Catalyst Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 3922368 | ⤷ Try a Trial |
| Japan | 5780521 | ⤷ Try a Trial |
| South Korea | 20070028459 | ⤷ Try a Trial |
| Jordan | 2832 | ⤷ Try a Trial |
| United Kingdom | 0022483 | ⤷ Try a Trial |
| Portugal | 1300396 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Catalyst Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1300396 | 420 | Finland | ⤷ Try a Trial | |
| 1300396 | C300565 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT ERVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .....016 20120723 |
| 1300396 | 300565 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT ERVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .....016 20120723 |
| 1300396 | 1290045-2 | Sweden | ⤷ Try a Trial | PRODUCT NAME: PERAMPANEL OCH SALTER OCH HYDRATER DAERAV; REG. NO/DATE: EU/1/12/776/001 20120723 |
| 1300396 | C01300396/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: PERAMPANEL; REGISTRATION NO/DATE: SWISSMEDIC 62440 14.12.2012 |
| 1764361 | PA2013017 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: PERAMPANELUM; REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016, 2012 07 23 EU/1/12/776/017 - EU1/12/776/023 20121029 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
